Nasdaq · CIK 0001790169
ZSTK Flora Growth Corp.
Insider trading from SEC Form 4. Last filing Dec 22, 2025.
Flora Growth Corp. (ZSTK) has 16 SEC Form 4 filings on file from 9 insiders, the latest filed on Dec 22, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Flora Growth Corp., scored.
Transactions
Every row filed, 26 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | Daniel Reis-Faria CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +471,208 | $0.00 | $0 | 471,208 | Dec 22, 2025 |
| Dec 19, 2025 | Dany Vaiman CFO | AGrant or award Employee Stock Option ("Right to Buy")derivative | +235,604 | $0.00 | $0 | 235,604 | Dec 22, 2025 |
| Dec 19, 2025 | Michael Heinrich Executive Chairman | AGrant or award Director Stock Option (Right to Buy)derivative | +471,208 | $0.00 | $0 | 471,208 | Dec 22, 2025 |
| Oct 23, 2025 | Michael Heinrich Executive Chairman | XIn-the-money exercise Convertible Promissory Notederivativeindirect: Held by Zero Gravity Labs Inc., a corporation owned and controlled by the Reporting Person | +4,902,220 | - | - | 4,902,220 | Oct 27, 2025 |
| Oct 22, 2025 | Michael John Brown director | AGrant or award Deferred Share Units ("DSUs")derivative | +7,468 | $0.00 | $0 | 94,421 | Oct 23, 2025 |
| Oct 9, 2025 | Daniel Reis-Faria CEO | POpen-market purchase Pre-Funded Token Warrantsderivative | +5,954,743 | $25.19 | $150M | 5,954,743 | Oct 10, 2025 |
| Jun 30, 2025 | Dany Vaiman CFO | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -342,888 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Harold Wolkin director | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -30,000 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Manfred Leventhal director | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -5,000 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Clifford Starke CEO | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -1,028,665 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Clifford Starke CEO | AGrant or award Stock Appreciation Rights ("SARs")derivative | +1,028,665 | - | - | 1,028,665 | Jul 2, 2025 |
| Jun 30, 2025 | Harold Wolkin director | AGrant or award Stock Appreciation Rights ("SARs")derivative | +30,000 | - | - | 30,000 | Jul 2, 2025 |
| Jun 30, 2025 | Manfred Leventhal director | AGrant or award Stock Appreciation Rights ("SARs")derivative | +5,000 | - | - | 5,000 | Jul 2, 2025 |
| Jun 30, 2025 | Dany Vaiman CFO | AGrant or award Stock Appreciation Rights ("SARs")derivative | +342,888 | - | - | 342,888 | Jul 2, 2025 |
| Jun 30, 2025 | Clifford Starke CEO | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -575,319 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Dany Vaiman CFO | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -191,773 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Clifford Starke CEO | AGrant or award Stock Appreciation Rights ("SARs")derivative | +575,319 | - | - | 575,319 | Jul 2, 2025 |
| Jun 30, 2025 | Dany Vaiman CFO | AGrant or award Stock Appreciation Rights ("SARs")derivative | +191,773 | - | - | 191,773 | Jul 2, 2025 |
| Jun 30, 2025 | Dany Vaiman CFO | DDisposition to issuer Stock Appreciation Rights ("SARs")derivative | -372,500 | - | - | 0 | Jul 2, 2025 |
| Jun 30, 2025 | Dany Vaiman CFO | AGrant or award Stock Appreciation Rights ("SARs")derivative | +372,500 | - | - | 372,500 | Jul 2, 2025 |
| Dec 15, 2024 | Sammy Dorf Executive Chairman | AGrant or award Common Shares | +250,000 | - | - | 250,000 | Dec 17, 2024 |
| Dec 15, 2024 | Manfred Leventhal director | AGrant or award Stock Appreciation Rights ("SARs")derivative | +5,000 | $0.00 | $0 | 5,000 | Dec 17, 2024 |
| Dec 15, 2024 | Clifford Starke CEO | AGrant or award Common Shares | +900,000 | - | - | 906,846 | Dec 17, 2024 |
| Dec 15, 2024 | Dany Vaiman CFO | AGrant or award Stock Appreciation Rights ("SARs")derivative | +372,500 | $0.00 | $0 | 372,500 | Dec 17, 2024 |
| Dec 15, 2024 | Harold Wolkin director | AGrant or award Stock Appreciation Rights ("SARs")derivative | +30,000 | $0.00 | $0 | 30,000 | Dec 17, 2024 |
| Dec 15, 2024 | Edward Woo director | AGrant or award Common Shares | +50,000 | - | - | 134,698 | Dec 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Michael John Browndirector
- Sammy DorfExecutive Chairman
- Michael HeinrichExecutive Chairman
- Manfred Leventhaldirector
- Daniel Reis-FariaCEO
- Clifford StarkeCEO
- Dany VaimanCFO
- Edward Woodirector
- Harold Wolkindirector
Questions about ZSTK
Answered from the filings on this page, as of the latest one.
Are insiders buying ZSTK?
No. In the last 90 days no insider at Flora Growth Corp. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ZSTK on the open market?
No open-market trade has been scored at Flora Growth Corp.. The latest Form 4 on file was filed on Dec 22, 2025 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Flora Growth Corp.?
9 people have filed a Form 4 at Flora Growth Corp., among them Michael John Brown (director), Sammy Dorf (Executive Chairman), Michael Heinrich (Executive Chairman). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.